Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial

IMPORTANCE: There are no approved medications for the core symptoms of autism spectrum disorder (ASD), socialization and communication difficulties. OBJECTIVE: To evaluate the efficacy and safety of balovaptan, an oral selective vasopressin 1a receptor antagonist, compared with placebo in children a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollander, Eric, Jacob, Suma, Jou, Roger, McNamara, Nora, Sikich, Linmarie, Tobe, Russell, Smith, Janice, Sanders, Kevin, Squassante, Lisa, Murtagh, Lorraine, Gleissl, Teresa, Wandel, Christoph, Veenstra-VanderWeele, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260643/
https://www.ncbi.nlm.nih.gov/pubmed/35793101
http://dx.doi.org/10.1001/jamapsychiatry.2022.1717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260643/
https://www.ncbi.nlm.nih.gov/pubmed/35793101
http://dx.doi.org/10.1001/jamapsychiatry.2022.1717

Ejemplares similares